Yuflyma, Biosimilar to Humira, Approved in EU for Chronic Inflammatory Diseases
IBD News, News
The European Commission (EC) has granted marketing authorization to Celltrion Healthcare‘s Yuflyma (CT-P17), a biosimilar to Humira (adalimumab). The marketing authorization includes all indications for which AbbVie’s Humira is approved, ... Read more